166 related articles for article (PubMed ID: 14613265)
21. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.
Catrina AI; Trollmo C; af Klint E; Engstrom M; Lampa J; Hermansson Y; Klareskog L; Ulfgren AK
Arthritis Rheum; 2005 Jan; 52(1):61-72. PubMed ID: 15641091
[TBL] [Abstract][Full Text] [Related]
22. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
Davis JC; Van Der Heijde D; Braun J; Dougados M; Cush J; Clegg DO; Kivitz A; Fleischmann R; Inman R; Tsuji W;
Arthritis Rheum; 2003 Nov; 48(11):3230-6. PubMed ID: 14613288
[TBL] [Abstract][Full Text] [Related]
23. Increased adiponectin levels in women with rheumatoid arthritis after etanercept treatment.
Lewicki M; Kotyla P; Kucharz E
J Rheumatol; 2009 Jun; 36(6):1346-7; author reply 1347. PubMed ID: 19509093
[No Abstract] [Full Text] [Related]
24. Etanercept in severe active rheumatoid arthritis: first Australian experience.
Perera LC; Tymms KE; Wilson BJ; Shadbolt B; Brook AS; Dorai Raj AK; Khoo KB
Intern Med J; 2006 Oct; 36(10):625-31. PubMed ID: 16958637
[TBL] [Abstract][Full Text] [Related]
25. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept.
Haraoui B; Keystone EC; Thorne JC; Pope JE; Chen I; Asare CG; Leff JA
J Rheumatol; 2004 Dec; 31(12):2356-9. PubMed ID: 15570634
[TBL] [Abstract][Full Text] [Related]
26. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial.
Kobelt G; Lindgren P; Singh A; Klareskog L
Ann Rheum Dis; 2005 Aug; 64(8):1174-9. PubMed ID: 15708879
[TBL] [Abstract][Full Text] [Related]
27. Improving outcomes in tumour necrosis factor a treatment: comparison of the efficacy of the tumour necrosis factor a blocking agents etanercept and infliximab in patients with active rheumatoid arthritis.
De Filippis L; Caliri A; Anghelone S; Scibilia G; Lo Gullo R; Bagnato G
Panminerva Med; 2006 Jun; 48(2):129-35. PubMed ID: 16953150
[TBL] [Abstract][Full Text] [Related]
28. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.
Buch MH; Bingham SJ; Bejarano V; Bryer D; White J; Reece R; Quinn M; Emery P
Arthritis Rheum; 2007 Apr; 57(3):448-53. PubMed ID: 17394231
[TBL] [Abstract][Full Text] [Related]
29. Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis.
Kekow J; Moots R; Khandker R; Melin J; Freundlich B; Singh A
Rheumatology (Oxford); 2011 Feb; 50(2):401-9. PubMed ID: 21059675
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study.
Weinblatt ME; Schiff MH; Ruderman EM; Bingham CO; Li J; Louie J; Furst DE
Arthritis Rheum; 2008 Jul; 58(7):1921-30. PubMed ID: 18576334
[TBL] [Abstract][Full Text] [Related]
31. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.
Heiberg MS; Nordvåg BY; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
Arthritis Rheum; 2005 Aug; 52(8):2506-12. PubMed ID: 16052584
[TBL] [Abstract][Full Text] [Related]
32. Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study.
Sokka T; Kautiainen H; Pincus T; Verstappen SM; Aggarwal A; Alten R; Andersone D; Badsha H; Baecklund E; Belmonte M; Craig-Müller J; da Mota LM; Dimic A; Fathi NA; Ferraccioli G; Fukuda W; Géher P; Gogus F; Hajjaj-Hassouni N; Hamoud H; Haugeberg G; Henrohn D; Horslev-Petersen K; Ionescu R; Karateew D; Kuuse R; Laurindo IM; Lazovskis J; Luukkainen R; Mofti A; Murphy E; Nakajima A; Oyoo O; Pandya SC; Pohl C; Predeteanu D; Rexhepi M; Rexhepi S; Sharma B; Shono E; Sibilia J; Sierakowski S; Skopouli FN; Stropuviene S; Toloza S; Valter I; Woolf A; Yamanaka H;
Arthritis Res Ther; 2010; 12(2):R42. PubMed ID: 20226018
[TBL] [Abstract][Full Text] [Related]
33. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
[TBL] [Abstract][Full Text] [Related]
34. A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis.
Bliddal H; Terslev L; Qvistgaard E; Konig M; Holm CC; Rogind H; Boesen M; Danneskiold-Samsøe B; Torp-Pedersen S
Scand J Rheumatol; 2006; 35(5):341-5. PubMed ID: 17062431
[TBL] [Abstract][Full Text] [Related]
35. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
Bansback NJ; Ara R; Barkham N; Brennan A; Fraser AD; Conway P; Reynolds A; Emery P
Rheumatology (Oxford); 2006 Aug; 45(8):1029-38. PubMed ID: 16782734
[TBL] [Abstract][Full Text] [Related]
36. Employment patterns and their effect on health outcomes among women with rheumatoid arthritis followed for 7 years.
Reisine S; Fifield J; Winkelman DK
J Rheumatol; 1998 Oct; 25(10):1908-16. PubMed ID: 9779843
[TBL] [Abstract][Full Text] [Related]
37. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
Park MC; Chung SJ; Park YB; Lee SK
Scand J Rheumatol; 2008; 37(3):173-8. PubMed ID: 18465450
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis.
Davis JC; van der Heijde DM; Braun J; Dougados M; Clegg DO; Kivitz AJ; Fleischmann RM; Inman RD; Ni L; Lin SL; Tsuji WH
Ann Rheum Dis; 2008 Mar; 67(3):346-52. PubMed ID: 17967833
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis.
Lovell DJ; Reiff A; Ilowite NT; Wallace CA; Chon Y; Lin SL; Baumgartner SW; Giannini EH;
Arthritis Rheum; 2008 May; 58(5):1496-504. PubMed ID: 18438876
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Symmons DP; Watson KD; Silman AJ;
Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]